Truist Raises Amgen (AMGN) Price Target While Morgan Stanley Signals Caution: Biotech Sector Dynamics

Truist elevated its price target for Amgen Inc. (NASDAQ:AMGN) to 340 from 327 on July 7, framing the adjustment within a broader Q2 earnings preview for the biotech sector. Analysts highlighted strength in commercial franchises and a robust catalyst calendar driving recent momentum, while sector optimism and deal activity were cited as key drivers.

■Truist anticipates a rebound from a traditionally softer start to the year, emphasizing Q2 commercial franchise performance.

■Morgan Stanley reduced its target to 333 on July 8, citing historical data on biotech's rate-sensitive performance in declining interest rate environments.

■Mizuho's Salim Syed updated his model post-Q1, raising the target to 303 last month.

Amgen, a global leader in human therapeutics discovery, development, and delivery, faces scrutiny amid biotech's sensitivity to interest rate fluctuations. While acknowledging its investment potential, analysts note that AI-focused equities may offer higher upside with lower risk. Investors seeking exposure to Trump-era tariffs and reshoring trends are directed toward undervalued AI stocks in complementary reports.

Dr. Yaman Ege Analysis: The conflicting price target adjustments underscore the biotech sector's vulnerability to macroeconomic rate pressures. Truist's optimism reflects confidence in commercial stability, whereas Morgan Stanley's caution signals strategic risk mitigation. Such volatility in analyst sentiment could indirectly influence TSMC-led semiconductor supply chains, particularly in high-stakes investment decisions tied to technological scalability.